Freiburg chemist Dr Tobias Schnitzer receives €1.5 million from the Vector Foundation to develop sustainable amidation reactions.

These reactions do not require toxic reagents and are highly energy-efficient. Schnitzer also relies on Artificial Intelligence in his research.

Amidations play a major role in the chemical industry. The new process could make an important contribution to more environmentally friendly production.

DTU researchers are behind a potentially groundbreaking antivenom that could revolutionize the treatment of venomous snakebites in Africa.

Artificial intelligence (AI) is profoundly transforming the paradigm of solid tumor drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, AI has significantly accelerated the discovery and validation of new targets, compressing the traditional ten-year research and development cycle to two to three years. Generative AI platforms have optimized small molecule inhibitors, biologics, and messenger RNA vaccines, achieving breakthroughs in overcoming tumor heterogeneity, improving efficacy, and predicting drug resistance. However, clinical translation still faces challenges such as data bias, algorithm transparency, and the validation gap between models and real-world human experience. This review aims to systematically elaborate on the transformative role of AI in solid tumor drug development and to promote interdisciplinary cooperation as well as the construction of ethical frameworks to enable the full realization of precision oncology.

Scientists reengineered chemo drug into spherical nucleic acids (SNAs), a globular form of DNA. Team tested the repackaged therapy on an animal model of acute myeloid leukemia, a fast-moving blood cancer. SNAs easily entered cancer cells and killed them from the inside while sparing healthy cells.